Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 45

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 45
---
 Inc. |     | Intellia Therapeutics, Inc.  |     | Xencor, Inc.                   |
| Cerevel Therapeutics, Inc.      |     | Mirati Therapeutics, Inc.    |     | Zentalis Pharmaceuticals (*)   |
| Crinetics Pharmaceuticals (*)   |     | REGENXBIO, Inc.              |     |                                |
| Deciphera Pharmaceuticals (*)   |     | Relay Therapeutics, Inc.     |     |                                |

(*) New to the 2024 Peer Group

Aon focused on developing a peer group that:

• comprised companies operating in the biopharmaceutical industries;

• captured comparable companies in terms of market capitalization, revenue, employee size and stage of development; and

• allowed for sufficient room for the company to grow.

The 2024 Peer Group represents a group of pre-commercial, later stage (companies in Phase 3 development and companies in the stages of submitting new-drug applications), oncology or neurology-focused biopharmaceutical/biotechnology companies, with a median market capitaliza tion of $1,631.8 million and a median of 314 employees at the time of review. Intra-Cellular Therapies, Inc., Karuna Therapeutics, Inc., Legend Biotech, Inc. and Reata Pharmaceuticals, Inc. were each removed from our peer group as their market capitalization and/or stage of development, as applicable, fell outside our targeted range, or due to acquisition, as applicable, and several new companies were added, as indicated in the table above, as they met all the required criteria outlined above. The peer group is used to support compensation decisions and is used for relative performance comparisons in the context of our incentive plans.

Based on the 2024 Peer Group, Aon prepared an assessment that included pay levels and compensation practices from publ ic SEC fili ngs. Aon supplemented the 2024 Peer Group proxy information with data from the Radford Global Compensation Survey, comprising 39 companies with a median headcount of 122 and a median market capitalization of $1.03 billion, which provides a broader market representation of companies and deeper position reporting. To arrive at competitive market

<div align='center'>33</div>

compensation, market data collected from the 2024 Peer Group and the Radford Global Compensation Survey was blended equally to form a composite assessment.

The peer group is used to support compensation decisions and is used for relative performance comparisons in the context of our